Laurie Eliason
About Laurie Eliason
Laurie Eliason is the Director of Patient Reported Outcomes Assessment at Bristol Myers Squibb, with over 20 years of experience in patient-centered outcomes and chronic disease epidemiology.
Current Title
Laurie Eliason is currently the Director of Patient Reported Outcomes Assessment at Bristol Myers Squibb. In this role, she focuses on evaluating and enhancing patient-reported outcomes, ensuring that the patient's voice is integral to the assessment of healthcare solutions.
Previous Work Experience
Laurie Eliason previously served as the Director of Value Evidence and Outcomes, Patient Centered Outcomes in Oncology at GlaxoSmithKline Pharma GmbH from 2018 to 2022. Before that, she worked at Evidera as a Research Scientist for 14 years, from 2004 to 2018. Her career also includes project management roles at Massachusetts General Hospital and WorldCare Clinical, LLC, as well as clinical research coordination at Brigham and Women's Hospital.
Education and Expertise
Laurie Eliason earned her Master of Public Health (MPH) in Chronic Disease Epidemiology from Yale University School of Medicine from 2002 to 2004. She also holds a Bachelor of Arts (BA) in Biology and French from Colby College, where she studied from 1995 to 1999. Her background in both biology and French complements her expertise in patient-centered outcomes and chronic disease epidemiology.
Patient-Centered Outcomes in Oncology
During her tenure at GlaxoSmithKline Pharma GmbH, Laurie Eliason worked on patient-centered outcomes in oncology. Her role involved ensuring that patient experiences and outcomes were central to the development and evaluation of oncology treatments. This highlighted her expertise in integrating patient perspectives into healthcare solutions.
Extensive Experience in Research Science
Laurie Eliason has extensive experience in research science, having worked at Evidera for 14 years as a Research Scientist. During this time, she contributed to numerous research projects, focusing on patient-centered outcomes and chronic disease epidemiology. Her long tenure at Evidera underscores her dedication and expertise in the field.